<DOC>
	<DOCNO>NCT00004293</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy toxicity glucocerebrosidase enzyme therapy patient Gaucher disease .</brief_summary>
	<brief_title>Phase II Study Glucocerebrosidase Patients With Gaucher Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat intravenous glucocerebrosidase every 2 week . The dose base clinical severity disease response therapy .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Gaucher disease glucocerebrosidase deficiency confirm enzymatic molecular assay At least 3 organ system affect , base follow criterion : Anemia Thrombocytopenia Organomegaly Bone deterioration radiograph Pulmonary compromise Symptoms compromise daily activity risk longevity No neurologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Gaucher 's disease</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>sphingolipidoses</keyword>
</DOC>